Holen Sie sich die Stockscreener-App
241.76
2.61%
-6.48
Handel nachbörslich:
242.00
0.24
+0.10%
Praxis Precision Medicines Inc Aktie (PRAX) Neueste Nachrichten
Praxis and Remagine partner to develop ulixacaltamide patch - scanx.trade
Praxis grants 951 RSUs to new employees under inducement plan - scanx.trade
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance UK
Fourteen new employees receive Praxis stock awards covering 3,478 shares. - Stock Titan
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Praxis Precision Medicines: Still Potential Upside After Huge Rally (Rating Upgrade) - Seeking Alpha
Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st
Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st
(PRAX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Sixty-six new employees receive stock awards from Praxis. They vest over four years. - Stock Titan
Praxis Precision Medicines (PRAX) Climbs 1.23% as Shares Press Toward $375.69 ResistanceRounding Top - careplusvn.com
PRAX Stock Price, Quote & News - Syfe
S&P 500 Futures Drop in Premarket Trading; Praxis Precision Meds, Science Applications Lead - Barron's
PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities - Yahoo Finance
Breakeven On The Horizon For Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Moomoo
PRAX Maintains by Goldman Sachs -- Price Target Raised to $575 - GuruFocus
Praxis Precision Medicines Slides as Investors Appear to Lock In Gains After Recent Rally - Quiver Quantitative
Goldman Sachs Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $575 - Moomoo
Praxis (PRAX) Update: Climbs 1.92% to $376.94 for the Current Session; the Supplied Trading Band Runs From $358.09 to $395.79Percent Below MA - vinanet.vn
Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock - Yahoo Finance
Praxis Precision Medicine Number of Employees 2026 | Employee Count & Headcount Data - reveliolabs.com
Oppenheimer Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $650 - Moomoo
Praxis Precision Medicines (NASDAQ:PRAX) Hits New 1-Year HighWhat's Next? - MarketBeat
Praxis Precision Medicines (NASDAQ:PRAX) Trading 6.3% HigherStill a Buy? - MarketBeat
Praxis Precision Medicines stock hits 52-week high at 388.27 USD - Investing.com Nigeria
Praxis Precision Medicines stock hits 52-week high at 388.27 USD - Investing.com
Praxis Precision Medicines stock hits 52-week high at 388.27 USD - Investing.com Canada
Praxis Precision Medicines Could Be Approaching 'Perfect Trifecta,' Oppenheimer Says - marketscreener.com
Raymond James Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Announces Target Price $945 - Moomoo
Raymond James raises Praxis Precision Medicines price target on pipeline outlook By Investing.com - Investing.com Australia
Raymond James raises Praxis Precision Medicines price target on pipeline outlook - Investing.com Australia
Raymond James raises Praxis Precision Medicines price target on pipeline outlook - Investing.com India
Raymond James raises Praxis Precision Medicines price target on pipeline outlook - Investing.com
Praxis Precision Medicines (PRAX) Holds Near $366.81 as Consolidation Tightens Between Key LevelsBlock Trade Flow - vinanet.vn
9,840 Shares in Praxis Precision Medicines, Inc. $PRAX Purchased by Handelsbanken Fonder AB - MarketBeat
Praxis Precision Medicines (PRAX): Orbis, Allan Gray disclose 5.5% ownership stake - Stock Titan
(PRAX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Praxis (PRAX) Q2 2026 Earnings Call Transcript - AOL.com
Praxis Precision Medicines (NASDAQ:PRAX) Reaches New 12-Month HighHere's Why - MarketBeat
PRAX Stock Drops 12% After Hours On Trial Setback — Retail Eyes FDA Approval Of Other Pipeline Candidates - Stocktwits
Praxis Precision Medicines (PRAX) Edges Higher as Biotech Momentum Holds Above Key SupportQuality Factor - dars.gov.et
4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year - TradingView
Equities Analysts Offer Predictions for PRAX Q3 Earnings - MarketBeat
Praxis Precision Medicines (PRAX) Edges Higher as Biotech Momentum Holds Above Key SupportWeak Sell Signals - vinanet.vn
H.C. Wainwright Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $1,201 - Moomoo
Weekly Recap: Cash runway into 2028 and RBC raises price target - TradingView
High Growth Tech Stocks in the US to Watch - simplywall.st
Dimensional Fund Advisors LP Has $10.04 Million Holdings in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
2.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):